The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NUWE | -96.15% | -100% | -92.97% | -100% |
| S&P | +13.92% | +85.3% | +13.13% | +412% |
Nuwellis, Inc. operates as a medical device company. It engages in the provision of products for the treatment of fluid overload. The firm's products include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
No news articles found for Nuwellis.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.22M | -6.3% |
| Gross Profit | $1.45M | -12.7% |
| Gross Margin | 65.18% | -4.8% |
| Market Cap | $3.02M | 36.1% |
| Market Cap / Employee | $79.58K | 0.0% |
| Employees | 38 | 0.0% |
| Net Income | $468.00K | -80.2% |
| EBITDA | -$2,654.00K | -82.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $3.09M | 62.2% |
| Accounts Receivable | $1.14M | -11.8% |
| Inventory | 2.2 | 17.4% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $128.00K | -65.2% |
| Short Term Debt | $255.00K | 9.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -225.22% | -57.8% |
| Return On Invested Capital | -196.25% | 128.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$3,245.00K | -32.2% |
| Operating Free Cash Flow | -$3,147.00K | -27.4% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 1.15 | -0.54 | -0.20 | -128.19% |
| Price to Sales | 0.43 | 0.47 | 0.23 | 0.34 | 91.24% |
| Price to Tangible Book Value | 27.40 | 26.45 | 11.32 | -0.20 | -94.77% |
| Enterprise Value to EBITDA | 0.35 | -0.69 | 0.74 | -0.04 | -82.50% |
| Return on Equity | -276.0% | -229.2% | -440.8% | -467.1% | -52.69% |
| Total Debt | $545.00K | $492.00K | $438.00K | $383.00K | -36.17% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
